RxDoctor Payments Data

Jackie Evans, MD

Family Medicine · Indianapolis, INNPI 1588657860

Payments from drug & device makers

$10,255in general payments, 2019–2025

Across 604 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • Lilly USA, LLC$1K
  • AstraZeneca$684
  • Amgen$487
  • Bayer$451
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$10,242100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,255 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$47,064
Medicare patients
173
Services billed
708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide103$112,699
JardianceEmpagliflozin61$66,981
EliquisApixaban45$48,302
JanuviaSitagliptin Phosphate15$25,173
MounjaroTirzepatide23$24,593
JanumetSitagliptin Phos/Metformin Hcl25$17,125
Breo ElliptaFluticasone/Vilanterol34$15,509
Soliqua 100-33Insulin Glargine/Lixisenatide14$12,545
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$12,463
EntrestoSacubitril/Valsartan11$7,445
ArexvyRsvpref3 Antigen/As01e/Pf24$7,311
Spiriva RespimatTiotropium Bromide11$5,700
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$5,172
ShingrixVaricella-Zoster Ge/As01b/Pf20$4,399
Gabapentin196$3,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,646$112,699103 claims
Boehringer IngelheimJardiance, Spiriva Respimat$364$72,68172 claims
PfizerEliquis$304$48,30245 claims
MerckJanuvia, Janumet$154$42,29840 claims
GSKBreo Ellipta, Trelegy Ellipta, Arexvy, Shingrix$419$39,68191 claims
Lilly USA, LLCMounjaro$1,057$24,59323 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$238$12,54514 claims
NovartisEntresto$161$7,44511 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$79$2,566318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →